

doi: 10.13241/j.cnki.pmb.2022.04.034

超声引导下竖脊肌平面阻滞与胸椎旁神经阻滞用于乳腺癌根治术 术后镇痛效果的比较 *

马丽雅¹ 原大江² 赵丽¹ 任强³ 药言伟¹

(1 山西医科大学麻醉学院 山西 太原 030000;

2 山西医科大学第二医院重症医学科 山西 太原 030000;3 山西医科大学第二医院麻醉科 山西 太原 030000)

摘要 目的: 比较超声引导下竖脊肌平面阻滞(ESPB)和胸椎旁神经阻滞(TPVB)用于乳腺癌根治术后镇痛的效果。**方法:** 2015年5月至2019年12月在山西医科大学第二医院接受乳腺癌根治术的64例患者,随机数字表法分为ESPB组和TPVB组,每组32例。在常规全身麻醉基础上,ESPB组行ESPB,TPVB组行TPVB,术后给予患者自控静脉镇痛(PCIA)。比较两组术后2、6、12、24、48 h 静息与咳嗽时视觉模拟评分(VAS)评分;比较两组患者术后PCIA首次按压时间,术后24 h PCIA镇痛泵按压次数、PCIA舒芬太尼用量,补救镇痛以及不良反应的发生率。**结果:** 两组患者术后各时间点静息和咳嗽时VAS评分间差异无统计学意义($P>0.05$);两组患者术后PCIA首次按压时间、术后24 h PCIA舒芬太尼用量以及补救镇痛的发生率间差异无统计学意义($P>0.05$);ESPB组患者术后24 h PCIA镇痛泵按压次数低于TPVB组,差异有统计学意义($P<0.05$);ESPB组和TPVB组术后恶心呕吐、皮肤瘙痒、呼吸抑制和头晕的发生率显比较差异无统计学意义($P>0.05$)。**结论:** 超声引导下ESPB相较于TPVB用于乳腺癌根治术患者术后镇痛效果相似,且不会增加不良反应的发生率,安全性较高,可替代TPVB为乳腺癌根治术患者提供良好的术后镇痛。

关键词: 乳腺癌根治术; 竖脊肌平面阻滞; 胸椎旁神经阻滞; 镇痛

中图分类号:R737.9 文献标识码:A 文章编号:1673-6273(2022)04-761-05

Comparison of Erector Spinae Plane Block and Thoracic Paravertebral Block Guided by Ultrasound on Postoperative Analgesia Effect after Radical Mastectomy*

MA Li-ya¹, YUAN Da-jiang², ZHAO Li¹, REN Qian³, YAO Yan-wei¹

(1 School of Anesthesiology, Shanxi Medical University, Taiyuan, Shanxi, 030000, China;

2 Department of Critical Care Medicine, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, 030000, China;

3 Department of Anesthesiology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, 030000, China)

ABSTRACT Objective: To compare the postoperative analgesia effect between erector spinae plane block (ESPB) and thoracic paravertebral block (TPVB) guided by ultrasound after radical mastectomy. **Methods:** From May 2015 to December 2019, 64 patients who underwent radical mastectomy in The Second Hospital of Shanxi Medical University were randomly divided into ESPB group and TPVB group, 32 cases in each group. On the basis of general anesthesia, ESPB group was given EspB, TPVB group was given TPVB, and patient-controlled intravenous analgesia (PCIA) was given after operation. The visual analogue scale (VAS) scores at rest and coughing at 2 h, 6 h, 12 h, 24 h and 48 h after operation were compared between the two groups. The first pressing time of PCIA, PCIA analgesia pump pressing times and dosage of PCIA sufentanil 24 h after operation, rescue analgesia and incidence of adverse reactions were compared between the two groups. **Results:** There was no significant difference in VAS scores between the two groups at rest and coughing at different time points after operation ($P>0.05$); There was no significant difference in first pressing time of PCIA, PCIA sufentanil 24 h after operation and the incidence of rescue analgesia between the two groups ($P>0.05$); The PCIA analgesia pump pressing times 24 h after operation in ESPB group were lower than those in TPVB group, the difference was statistically significant ($P<0.05$); There was no significant difference in the incidence of postoperative nausea and vomiting, skin itching, respiratory depression and dizziness between ESPB group and TPVB group ($P>0.05$). **Conclusion:** Compared with TPVB, ESPB guided by ultrasound has similar analgesic effect in patients with radical mastectomy, and it does not increase the incidence of adverse reactions. It has higher safety and can replace TPVB to provide good postoperative analgesia for patients with radical mastectomy.

Key words: Radical mastectomy; Erector spinae plane block; Thoracic paravertebral block; Analgesia**Chinese Library Classification(CLC):** R737.9 **Document code:** A**Article ID:** 1673-6273(2022)04-761-05

* 基金项目:山西省医学科研基金项目(ZL1400238)

作者简介:马丽雅(1993-),女,硕士研究生,研究方向:伤害性信号传入和器官损伤与保护,E-mail: ma18835161753@163.com

(收稿日期:2021-05-21 接受日期:2021-06-17)

前言

乳腺癌根治术是治疗乳腺癌的主要方式,由于手术范围广、创伤大,因此手术后疼痛的发生率很高。有研究发现,约40%的接受乳腺癌根治手术的患者术后急性疼痛评分超过5分^[1-3]。严重的术后疼痛可能会导致患者出现应激反应,如血压升高、心率增快,从而进一步延长住院时间,增加住院费用^[4-6]。此外,乳腺癌根治手术后患者慢性疼痛的发生率和长期使用阿片类药物的风险分别为29%和11%,严重影响患者的生活质量^[7-10]。目前,胸椎旁阻滞(thoracic paravertebral block, TPVB)被认为是乳腺癌手术后镇痛模式的金标准,且已成为围手术期多模式镇痛的重要组成部分^[11,12]。然而,其解剖上接近胸膜和脊神经根,对于实施TPVB操作者的技术要求较高,并且发生霍纳综合征、硬膜外注射和气胸等并发症的风险较高^[13-15]。竖脊肌平面阻滞(erector spinae plane block, ESPB)是一种新型的区域镇痛技术,有研究报道^[16-19],将ESPB应用于乳腺癌手术,可以

提供良好的术后镇痛效果。本研究旨在比较ESPB与TPVB用于乳腺癌根治手术后镇痛的有效性和安全性。

1 资料与方法

1.1 一般资料

选取本院自2015年5月至2019年12月收治的经乳腺外科行手术后病理确诊的乳腺癌手术患者64例,纳入标准:(1)经病理确诊并且符合乳腺癌根治术适应证;(2)美国麻醉医师协会(ASA)分级为I~II级;(3)年龄40~65岁。排除标准:(1)严重心、肝、肾功能及凝血功能障碍患者;(2)对局麻药物过敏的患者;(3)妊娠期、哺乳期妇女;(4)无法耐受手术及麻醉的患者。采取随机数字表法分为ESPB组与TPVB组,每组各32例,两组患者的一般情况差异均无统计学意义($P>0.05$),见表1。本研究经我院医学伦理委员会审核通过,并与所有患者或家属签署知情同意书。

表1 ESPB组与TPVB组患者一般情况比较($\bar{x}\pm s$)

Table 1 Comparison of baseline data between ESPB group and TPVB group

Groups	n	Age(years)	Height(cm)	Weight(Kg)	ASA(I/II)	Operative time(min)
ESPB group	32	49.88±3.19	161.19±4.55	53.31±5.04	15/17	120.69±4.24
TPVB group	32	50.91±5.02	159.94±4.00	52.16±4.55	16/16	120.34±3.30
t/χ^2		-0.981	1.175	0.962	0.062	0.363
P		0.331	0.259	0.348	0.802	0.725

1.2 麻醉方法

术前常规禁食禁饮。入室后常规监测血压(NIBP)、心率(HR)、心电、血氧饱和度(SpO₂)和脑电双频指数(BIS),开放健侧外周静脉通路。患者均行静吸复合麻醉,诱导方式为静脉注射咪达唑仑2 mg、舒芬太尼0.5 μg·kg⁻¹、丙泊酚2 mg·kg⁻¹和顺苯磺酸阿曲库铵0.15 mg·kg⁻¹,满足插管条件后,行气管插管和机械通气,潮气量6-8 mL·kg⁻¹,频率为12-20次/分,吸呼比为1:2,术中呼吸末二氧化碳(ETCO₂)维持在35~45 mmHg之间。使用丙泊酚2~8 mg·kg⁻¹·h⁻¹、瑞芬太尼0.1~0.3 μg·kg⁻¹·min⁻¹、七氟醚1%~2%进行麻醉维持,间断追加顺苯磺酸阿曲库铵0.05 mg·kg⁻¹维持肌肉松弛。维持BIS在40~60范围内。手术完成待患者符合拔管条件后拔除气管插管。所有患者均安装自控镇痛泵实施PCIA。其配方为舒芬太尼100 μg、氟哌利多2.5 mg溶入98 mL 0.9%氯化钠注射液。设置单次剂量为0.5 mL,背景输注量2 mL·h⁻¹,锁定时间为15 min。

1.3 镇痛方法

在麻醉诱导后,ESPB组患者行超声引导下竖脊肌平面阻滞,患者取健侧卧位,穿刺部位消毒铺巾,于第5胸椎水平、向后中线手术侧旁开3 cm处进针,穿刺回抽无空气、血液和脑脊液后,将0.375%罗哌卡因20 mL注入横突和竖脊肌筋膜间隙。TPVB组患者行超声引导下胸椎旁神经阻滞,患者取健侧卧位,探头定位于T3和T5胸椎旁间隙,清晰显示横突和胸膜的超声图像,缓慢进针突破肋横突韧带,穿刺进针至椎旁间隙回抽无血液、脑脊液后,注射0.375%罗哌卡因20 mL。

1.4 观察指标

由一名对分组不知情的麻醉医生记录两组患者术后2 h、6 h、12 h、24 h、48 h的静息和咳嗽时VAS评分(VAS评分:0分:无痛;>0分,≤3分:轻微疼痛,且尚能忍受;4~6分:疼痛影响睡眠,但尚能忍受;7~10分:疼痛剧烈,影响食欲和睡眠)^[20]。当患者VAS评分大于4分时,静脉注射曲马多50 mg作为补救镇痛治疗,记录补救患者例数;记录两组患者术后PCIA首次按压时间、术后24 h PCIA按压次数、PCIA舒芬太尼用量;记录两组患者术后不良反应的发生率。

1.5 统计分析

采用SPSS 22.0统计软件对数据进行统计分析。正态分布计量资料以均数±标准差($\bar{x}\pm s$)表示,组间比较采用成组t检验;计数资料以[n(%)]表示,使用 χ^2 检验, $P<0.05$ 为差异有统计学意义。

2 结果

2.1 两组各时间点下静息时VAS评分比较

两组患者术后2 h、6 h、12 h、24 h、48 h静息VAS评分无明显差异($P>0.05$),见表2。

2.2 两组各时间点下咳嗽时VAS评分比较

两组患者术后2 h、6 h、12 h、24 h、48 h咳嗽VAS评分无明显差异($P>0.05$),见表3。

2.3 两组术后24 h内PCIA的应用以及补救镇痛

两组术后24 h PCIA镇痛泵按压次数比较,ESPB组低于TPVB组,差异有统计学意义($P<0.05$),而两组术后PCIA首次按压时间、术后24 h PCIA舒芬太尼累计用量及术后补救镇

痛无统计学差异($P<0.05$),见表4。

2.4 不良反应的情况

术后不良反应发生情况比较,ESPB组术后恶心呕吐3例,

皮肤瘙痒2例,呼吸抑制2例,头晕1例。TPVB组术后恶心呕吐4例,皮肤瘙痒1例,呼吸抑制2例,头晕2例,差异均无统计学意义($P>0.05$),见表5。

表2 ESPB组与TPVB组患者术后不同时点静息时VAS评分的比较($\bar{x}\pm s$)

Table 2 Comparison of VAS scores at rest between ESPB group and TPVB group at different time points after operation($\bar{x}\pm s$)

Groups	n	2h	6h	12h	24h	48h
ESPB group	32	1.73±0.65	2.78±0.43	3.33±0.24	3.22±0.21	3.07±0.31
TPVB group	32	1.67±0.56	2.74±0.35	3.24±0.28	3.29±0.29	3.0±0.30
t		0.431	0.322	1.293	-0.961	0.855
P		0.665	0.752	0.201	0.343	0.402

表3 ESPB组与TPVB组患者术后不同时点咳嗽时VAS评分的比较($\bar{x}\pm s$)

Table 3 Comparison of VAS scores at coughing between ESPB group and TPVB group at different time points after operation($\bar{x}\pm s$)

Groups	n	2h	6h	12h	24h	48h
ESPB group	32	2.37±0.31	3.03±0.14	3.57±0.20	3.50±0.22	3.39±0.23
TPVB group	32	2.24±0.24	3.17±0.27	3.50±0.24	3.57±0.19	3.35±0.18
t		1.901	-2.543	1.333	-1.164	0.711
P		0.604	0.143	0.794	0.256	0.824

表4 ESPB组与TPVB组患者术后24 h内PCIA的应用以及补救镇痛

Table 4 The application of PCIA and salvage analgesia within 24 hours after operation between ESPB group and TPVB group

Groups	n	First pressing time of PCIA(h)	PCIA analgesia pump pressing times 24h after operation(n)	Dosage of PCIA sufentanil 24h after operation(ug)	Rescue analgesia[n(%)]
ESPB group	32	8.97±2.92	4.97±1.64	20.06±2.96	3(9.37)
TPVB group	32	10.00±3.25	6.09±1.59	20.25±2.83	5(15.62)
t/ χ^2		-1.332	-2.795	-0.266	0.572
P		0.193	0.007	0.068	0.713

表5 ESPB组与TPVB组患者不良反应发生率比较[n(%)]

Table 5 Comparison of adverse reaction rates between EspB group and TPVB group

Groups	n	Nausea and vomiting	Skin itching	Respiratory depression	dizziness
ESPB group	32	3(9.38)	2(6.25)	2(6.25)	1(3.12)
TPVB group	32	4(12.5)	1(3.12)	2(6.25)	2(6.25)
χ^2		0.163	0.352	0.001	0.353
P		0.695	1.006	1.005	0.552

3 讨论

临床对乳腺癌的治疗方式以腋窝淋巴结清扫术和全乳房切除根治术为主,常影响到乳腺周围各种神经,致使术后的静脉镇痛效果欠佳。另外,20%~68%的乳腺癌患者术后疼痛可以发展成慢性疼痛,此类慢性疼痛主要由外周感受器损伤所致,表现为神经痛^[21,22]。目前临幊上可以通过阻滞外周神经从而阻断外周伤害性刺激信号向中枢神经的传递通道,有术后镇痛和辅助麻醉的疗效。乳腺癌根治手术后镇痛方式多样,TPVB被认为是乳腺手术后镇痛的金标准。然而,研究认为TPVB存在潜在的并发症,如气胸、局麻药误入硬膜外腔^[23-25]。近年来,新兴的超声引导下筋膜平面阻滞技术在乳腺手术中得到了广泛的应用,主要包括ESPB、前锯肌平面阻滞和胸筋膜平面阻

滞。ESPB由Forero M等^[23]在2016年首次报道用于胸背部神经疼痛治疗,随后应用于乳腺手术围术期镇痛。尽管研究认为ESPB在技术上相比于TPVB更容易实施,但ESPB的相对有效性和安全性尚未完全被证实^[26,27]。

袁炳林等^[28]研究表明TPVB对乳腺癌改良根治术后4 h和术后12 h的VAS评分均低于对照组患者。既往报道显示^[29],胸神经II阻滞乳腺癌改良根治术后镇痛效果可维持8 h以上,同时其还能够较单纯全身麻醉降低病人VAS评分,减少阿片类药物用量,但目前尚少研究对ESPB与TPVB静息及咳嗽VAS评分进行比较,本研究结果表明ESPB在乳腺癌根治术后2 h、6 h、12 h、24 h、48 h静息和咳嗽时VAS评分方面与TPVB是相似的,说明两种神经阻滞在乳腺癌根治术后镇痛上无差异。

本研究表明两组术后PCIA首次按压时间、术后24 h PCIA

舒芬太尼用量以及补救镇痛的发生率间差异无统计学意义,但ESPB组患者术后24 h PCIA 镇痛泵按压次数低于TPVB组,这表明ESPB较TPVB阻滞时间更持久,可更有效地抑制暴发性疼痛,这可能与椎旁神经阻滞直接浸润包裹神经,椎旁间隙通过内侧的椎间孔与硬膜外腔相通有关,部分局麻药可进入硬膜外腔致对应节段的硬膜外阻滞等相关。Gürkan Y等^[30]研究表明,ESPB组与TPVB组术后24 h 阿片类药物累计消耗量无明显差异,这与我们的研究结论是一致的。本研究将0.375%罗哌卡因20 mL注射到竖脊肌筋膜间隙和横突表面,可产生T3-T8的前胸、后部及侧胸壁的皮区感觉阻滞,阻断了脊神经的背侧支和腹侧支。目前,关于竖脊平面阻滞的作用机制尚存在争议。Schwartzmann A等^[14]的尸体解剖研究表明,造影剂在竖脊肌下方的头尾方向广泛扩散,可以扩散到硬膜外间隙、椎旁间隙和肋间间隙,最终沉积在靠近横突尖端的竖脊肌下方。然而,Ivanusic J等^[13]在研究中发现,在被染料注射的10具尸体中,仅有2具尸体解剖中有染料扩散到背侧支,其作用机制可能与肋间神经外侧皮支的神经元传递中断有关。

本研究中,两组术后恶心与呕吐、呼吸抑制、皮肤瘙痒和头晕发生率比较无明显差异。结果显示,超声引导下ESPB用于乳腺癌根治手术后镇痛安全性高,镇痛效果好。Swisher MW等^[31]研究相同结果显示,超声引导下ESPB和TPVB用于乳腺手术后镇痛的不良反应和补救镇痛例数无差异。本研究中,两种镇痛方法均未出现操作不当引起的并发症,但有报道称,当实施TPVB阻滞时,由于穿刺针靠近胸膜和椎管,有发生气胸和蛛网膜阻滞风险。因此,大多数学者认为TPVB技术难度系数较高且风险较大^[32-34]。相反,ESPB位置表浅,竖脊肌和横突在超声下容易识别,且ESPB远离重要器官和血管。因此,在两种阻滞镇痛效果相似的基础上,ESPB可以作为TPVB的一种替代方法,安全的用于乳腺癌手术后镇痛。

综上所述,超声引导下ESPB相较于TPVB用于乳腺癌根治患者术后镇痛效果相似,且不会增加不良反应的发生率,安全性较高,可替代TPVB为乳腺癌根治术患者提供良好的术后镇痛。

参考文献(References)

- [1] Marazzi F, Masiello V, Marchesano D, et al. Shoulder girdle impairment in breast cancer survivors: the role of range of motion as predictive factor for dose distribution and clinical outcome [J]. Tumori, 2019, 105(4): 319-330
- [2] Klein I, Kalichman L, Chen N, et al. Effect of physical activity levels on oncological breast surgery recovery: a prospective cohort study[J]. Sci Rep, 2021, 11(1): 10432
- [3] Paolucci T, Bernetti A, Bai AV, et al. The sequelae of mastectomy and quadrantectomy with respect to the reaching movement in breast cancer survivors: evidence for an integrated rehabilitation protocol during oncological care[J]. Support Care Cancer, 2021, 29(2): 899-908
- [4] Bao T, Seidman A, Li Q, et al. Living with chronic pain: perceptions of breast cancer survivors [J]. Breast Cancer Res Treat, 2018, 169(1): 133-140
- [5] Roth RS, Qi J, Hamill JB, et al. Is chronic postsurgical pain surgery-induced? A study of persistent postoperative pain following breast reconstruction[J]. Breast, 2018, 37: 119-125
- [6] Soldera SV, Ennis M, Lohmann AE, et al. Sexual health in long-term breast cancer survivors [J]. Breast Cancer Res Treat, 2018, 172(1): 159-166
- [7] Buscariollo DL, Cronin AM, Borstelmann NA, et al. Impact of pre-diagnosis depressive symptoms and health-related quality of life on treatment choice for ductal carcinoma in situ and stage I breast cancer in older women[J]. Breast Cancer Res Treat, 2019, 173(3): 709-717
- [8] Chiang D, Rice DA, Helsby NA, et al. The Prevalence, Impact, and Risk Factors for Persistent Pain After Breast Cancer Surgery in a New Zealand Population[J]. Pain Med, 2019, 20(9): 1803-1814
- [9] Habib AS, Kertai MD, Cooter M, et al. Risk factors for severe acute pain and persistent pain after surgery for breast cancer: a prospective observational study[J]. Reg Anesth Pain Med, 2019, 44(2): 192-199
- [10] Patel SJ, Augoustides J. Serratus Anterior Plane Block-A Promising Technique for Regional Anesthesia in Minimally Invasive Cardiac Surgery[J]. J Cardiothorac Vasc Anesth, 2020, 34(11): 2983-2985
- [11] 罗洁,曹洪,刘国文.超声引导TPVB与全麻在乳腺癌保乳术快速康复中的应用比较[J].中国现代手术学杂志,2019,23(4): 317-320
- [12] Kulhari S, Bharti N, Bala I, et al. Efficacy of pectoral nerve block versus thoracic paravertebral block for postoperative analgesia after radical mastectomy: a randomized controlled trial [J]. Br J Anaesth, 2016, 117(3): 382-386
- [13] Ivanusic J, Konishi Y, Barrington MJ. A Cadaveric Study Investigating the Mechanism of Action of Erector Spinae Blockade [J]. Reg Anesth Pain Med, 2018, 43(6): 567-571
- [14] Schwartzmann A, Peng P, Maciel MA, et al. Mechanism of the erector spinae plane block: insights from a magnetic resonance imaging study[J]. Can J Anaesth, 2018, 65(10): 1165-1166
- [15] Aksu C, Kuş A, Yörükoglu HU, et al. Analgesic effect of the bi-level injection erector spinae plane block after breast surgery: A randomized controlled trial[J]. Agri, 2019, 31(3): 132-137
- [16] Chin KJ, Barrington MJ. Erector Spinae Block: A Magic Bullet for Postoperative Analgesia? [J]. Anesth Analg, 2019, 129(1): 8-9
- [17] Singh S, Kumar G, Akhileshwar. Ultrasound-guided erector spinae plane block for postoperative analgesia in modified radical mastectomy: A randomised control study [J]. Indian J Anaesth, 2019, 63(3): 200-204
- [18] Altparmak B, Korkmaz Toker M, Uysal AJ, et al. Comparison of the effects of modified pectoral nerve block and erector spinae plane block on postoperative opioid consumption and pain scores of patients after radical mastectomy surgery: A prospective, randomized, controlled trial[J]. J Clin Anesth, 2019, 54: 61-65
- [19] Wang X, Ran G, Chen X, et al. The Effect of Ultrasound-Guided Erector Spinae Plane Block Combined with Dexmedetomidine on Postoperative Analgesia in Patients Undergoing Modified Radical Mastectomy: A Randomized Controlled Trial[J]. Pain Ther, 2021, 10 (1): 475-484
- [20] Sung YT, Wu JS. The Visual Analogue Scale for Rating, Ranking and Paired-Comparison (VAS-RRP): A new technique for psychological measurement [J]. Behav Res Methods, 2018, 50 (4): 1694-1715
- [21] 魏鑫,杨凯,高晓秋,等.竖脊肌平面阻滞与胸椎旁神经阻滞用于乳

- 腺癌根治术围术期镇痛效果的比较[J].临床麻醉学杂志, 2020, 36(9): 871-875
- [22] 赵怡, 贾香美. 乳腺癌根治术后慢性疼痛的影响因素分析[J]. 中国医学前沿杂志(电子版), 2019, 11(1): 118-121
- [23] Forero M, Adhikary SD, Lopez H, et al. The Erector Spinae Plane Block: A Novel Analgesic Technique in Thoracic Neuropathic Pain [J]. Reg Anesth Pain Med, 2016, 41(5): 621-627
- [24] Huan S, Deng Y, Wang J, et al. Efficacy and safety of paravertebral block versus intercostal nerve block in thoracic surgery and breast surgery: A systematic review and meta-analysis [J]. PLoS One, 2020, 15(10): e0237363
- [25] Lin ZM, Li MH, Zhang F, et al. Thoracic Paravertebral Blockade Reduces Chronic Postsurgical Pain in Breast Cancer Patients: A Randomized Controlled Trial[J]. Pain Med, 2020, 21(12): 3539-3547
- [26] Niesen AD, Jacob AK, Law LA, et al. Complication rate of ultrasound-guided paravertebral block for breast surgery [J]. Reg Anesth Pain Med, 2020, 45(10): 813-817
- [27] Seelam S, Nair AS, Christopher A, et al. Efficacy of single-shot ultrasound-guided erector spinae plane block for postoperative analgesia after mastectomy: A randomized controlled study [J]. Saudi J Anaesth, 2020, 14(1): 22-27
- [28] 袁炳林, 黄焕森, 赖洁兰, 等. 胸椎旁神经阻滞麻醉对乳腺癌改良根治术后镇痛的效果[J]. 中国医刊, 2021, 56(1): 103-105
- [29] 陈祖涛, 张立群, 韩俊. 不同神经阻滞方案对乳腺癌改良根治术后镇痛效果的影响[J]. 安徽医药, 2021, 25(1): 104-107
- [30] Gürkan Y, Aksu C, Kuş A, et al. Erector spinae plane block and thoracic paravertebral block for breast surgery compared to IV-morphine: A randomized controlled trial [J]. J Clin Anesth, 2020, 59: 84-88
- [31] Swisher MW, Wallace AM, Sztain JF, et al. Erector spinae plane versus paravertebral nerve blocks for postoperative analgesia after breast surgery: a randomized clinical trial [J]. Reg Anesth Pain Med, 2020, 45(4): 260-266
- [32] Sharma S, Arora S, Jafra A, et al. Efficacy of erector spinae plane block for postoperative analgesia in total mastectomy and axillary clearance: A randomized controlled trial[J]. Saudi J Anaesth, 2020, 14(2): 186-191
- [33] Santonastaso DP, de Chiara A, Russo E, et al. A possible future for anaesthesia in breast surgery: thoracic paravertebral block and awake surgery. A prospective observational study [J]. Tumori, 2021, 107(2): 125-131
- [34] Zhang Y, Liu T, Zhou Y, et al. Analgesic efficacy and safety of erector spinae plane block in breast cancer surgery: a systematic review and meta-analysis[J]. BMC Anesthesiol, 2021, 21(1): 59

(上接第 654 页)

- [17] 杨松涛, 崔海燕. 血清炎性因子 TNF- α 、IL-6、ICAM-1 水平变化在冠心病心绞痛诊断中的应用价值[J]. 贵州医药, 2020, 44(2): 297-298
- [18] Tian Y, Deng P, Li B, et al. Treatment models of cardiac rehabilitation in patients with coronary heart disease and related factors affecting patient compliance [J]. Rev Cardiovasc Med, 2019, 20(1): 27-33
- [19] 刘旭辉, 钱文浩, 方翔, 等. 替格瑞洛联合瑞舒伐他汀钙片对冠心病患者心功能、凝血功能及基质金属蛋白酶的影响[J]. 现代生物医学进展, 2020, 20(15): 2967-2970, 3000
- [20] Franchi F, Rollini F, Rivas A, et al. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention[J]. Circulation, 2019, 139(14): 1661-1670
- [21] Niezgoda P, Sikora J, Barańska M, et al. Crushed sublingual versus oral ticagrelor administration strategies in patients with unstable angina. A pharmacokinetic/pharmacodynamic study [J]. Thromb Haemost, 2017, 117(4): 718-726
- [22] Feng W, Liu D, Wang Y, et al. Effects of food and gender on pharmacokinetics of ticagrelor and its main active metabolite AR-C124910XX in healthy Chinese subjects[J]. Int J Clin Pharmacol Ther, 2018, 56(8): 372-380
- [23] Zaman M, Bajwa RI, Saeed S, et al. Synthesis and characterization of thiol modified beta cyclodextrin, its biocompatible analysis and application as a modified release carrier of ticagrelor [J]. Biomed Mater, 2020, 16(1): 015023
- [24] 焦子贻, 沈丹丹, 李月, 等. 基于中医传承辅助平台分析治疗冠心病心绞痛中药复方的用药规律[J]. 天津中医药大学学报, 2021, 40(1): 36-41
- [25] 甘一立. 中西医结合治疗冠心病心绞痛临床观察 [J]. 实用中医药杂志, 2020, 36(5): 638-639
- [26] 阮小芬, 王英杰, 邵春林, 等. 葛兰心宁软胶囊治疗冠心病心绞痛的临床效果及对脂质代谢的影响 [J]. 中国医药导报, 2017, 14(18): 138-141, 152
- [27] Gori T. Exogenous NO Therapy for the Treatment and Prevention of Atherosclerosis[J]. Int J Mol Sci, 2020, 21(8): 2703
- [28] Leurgans TM, Bloksgaard M, Irmukhamedov A, et al. Relaxing Responses to Hydrogen Peroxide and Nitric Oxide in Human Pericardial Resistance Arteries Stimulated with Endothelin-1 [J]. Basic Clin Pharmacol Toxicol, 2018, 122(1): 74-81
- [29] 李琳, 王燕, 苏林, 等. 冠心病及心肌梗死后心力衰竭病人血管内皮功能障碍与中医证型的相关性研究[J]. 中西医结合心脑血管病杂志, 2016, 14(14): 1569-1572
- [30] 潘洪平. 葛根总黄酮和葛根素的药理作用和临床应用研究进展[J]. 广西医学, 2003, 25(10): 1941-1944
- [31] Rigeltsky JM, Sweet BV. Hawthorn: pharmacology and therapeutic uses[J]. Am J Health Syst Pharm, 2002, 59(5): 417-422